| abstract |
Provided herein are dendrimers comprising a core unit, five generations of building units being a lysine residue or analogue thereof, a plurality of first terminal groups each comprising a residue of a nucleoside analogue, and a plurality of second terminal groups each comprising a hydrophilic polymeric group. Also provided herein are pharmaceutical compositions comprising the dendrimer, and methods and uses of the dendrimers in therapy of disorders such as cancers. |